Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 5/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 9/20 | 0.40 |
| ▸ | TCF7L2 | Q9NQB0 | 9/20 | 0.40 |
| ▸ | CDK1 | P06493 | 4/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | PDE6D | O43924 | 1/20 | 0.34 |
| ▸ | PDE6A | P16499 | 1/20 | 0.34 |
| ▸ | PDE6G | P18545 | 1/20 | 0.34 |
| ▸ | PDE6B | P35913 | 1/20 | 0.34 |
| ▸ | PDE6C | P51160 | 1/20 | 0.34 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7496427 | 0.92 | PDE5A (0.38) | PDE5ACTNNB1TCF7L2CDK1HRH4 | |
| SCHEMBL7500882 | 0.91 | PDE5A (0.40) | PDE5ACTNNB1TCF7L2CDK1HRH4 | |
| SCHEMBL7499010 | 0.91 | PDE5A (0.43) | PDE5ACTNNB1TCF7L2CDK1HRH4 | |
| SCHEMBL7496919 | 0.88 | CTNNB1 (0.43) | PDE5ACTNNB1TCF7L2HRH4BRD4 | |
| SCHEMBL7794605 | 0.87 | PDE5A (0.56) | PDE5ACTNNB1TCF7L2 | |
| SCHEMBL7499155 | 0.85 | PDE5A (0.40) | PDE5ACTNNB1TCF7L2CDK1HRH4 | |
| SCHEMBL7957257 | 0.85 | CTNNB1 (0.38) | PDE5ACTNNB1TCF7L2CDK1HRH4 | |
| SCHEMBL7497340 | 0.80 | PDE5A (0.56) | PDE5APDE6DPDE6APDE6GPDE6B | |
| Hydrochloric Acid SCHEMBL7497602 | 0.80 | CTNNB1 (0.42) | PDE5ACTNNB1TCF7L2HRH4BRD4 | |
| SCHEMBL7496433 | 0.79 | PDE5A (0.53) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031760-A1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | PAMUKCU RIFAT (US) | 2001-10-18 | — | — | US | disclosed |
| US-6262059-B1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | CELL PATHWAYS, INC. | 2001-07-17 | — | — | US | disclosed |
| US-5576322-A | Anti-ischemic 2,4-diaminoquinazolines | EISAI CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0607439-A1 | NITROGENOUS HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 1994-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031760-A1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | MKI67, PCNA, NQO2 | PDE5A 2260/4885CTNNB1 2966/4885TCF7L2 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.